Bowel cancer test rolls out in Blue Mountains
28 July, 2014 by Dylan Bushell-EmblingClinical Genomics has launched a trial rollout of its jointly developed blood test for bowel cancer in the Blue Mountains.
Novogen picks CMOs for ovarian cancer drug
28 July, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) joint venture CanTx has chosen two US-based CMOs to manufacture batches of Cantrixil, the ovarian cancer drug candidate it aims to take to the clinic in mid-2015.
Patrys commences CAR T cell research program
24 July, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has started collaborative research into genetically engineering T cells against novel anticancer targets using its IgM antibodies.
Fellowships for research in Japan
24 July, 2014Postdoctoral, short- and long-term research fellowships are available to Australian researchers to work in Japan for 2015-2016.
ImpediMed picks Australian site for L-Dex trial
23 July, 2014 by Dylan Bushell-EmblingImpediMed (ASX:IPD) has named the Macquarie University Cancer Institute as the Australian site for a post-approval trial of L-Dex, its lymphodoema detection device.
Developing guidelines for 'omics'-based tests
23 July, 2014A new guide for 'omics'-based tests, focusing on genomic testing, has been released for public consultation by the NHMRC.
Biotron's BIT225 reverses immune impairment in HIV
23 July, 2014 by Dylan Bushell-EmblingNew data from a trial of Biotron's (ASX:BIT) BIT225 in HIV show that patients treated daily demonstrated a reduction in sCD163 levels in the blood.
Virax appoints oncology guru to scientific board
21 July, 2014 by Dylan Bushell-EmblingVirax Holdings (ASX:VHL) has selected US cancer specialist Dr Joseph Sparano to lead phase I/IIb trials of breast cancer treatment candidate GGTI-2418.
Shutting the gate on the malaria parasite
18 July, 2014Blocking the malaria parasite's access to proteins needed for its survival may lead to the development of new treatments for this deadly disease.
New initiative for health research and its translation
17 July, 2014The NHMRC has launched the Advanced Health Research and Translation Centre initiative.
Imugene picks exclusive manufacturer for HER-Vaxx
16 July, 2014 by Dylan Bushell-EmblingImugene (ASX:IMU) has selected Swiss-based virosome specialist Mymetics as the exclusive manufacturer for its HER-Vaxx cancer immunotherapy product.
Prima picks up US patent for cancer treatment CVac
16 July, 2014 by Dylan Bushell-EmblingThe US patent office has approved Prima BioMed's (ASX:PRR) application for a patent protecting autologous cancer treatment candidate CVac.
Funding diabetes
11 July, 2014A new ARC Special Research Initiative for Type 1 juvenile diabetes will see $35 million committed to research into this disease.
Regeneus secures rights to cancer vaccine for humans
08 July, 2014 by Dylan Bushell-EmblingRegeneus (ASX:RGS) has picked up exclusive rights to an autologous therapeutic cancer vaccine for humans, after having already secured the exclusive licence for veterinary applications.
Imugene appoints new director
07 July, 2014 by Dylan Bushell-EmblingImugene's (ASX:IMU) second-largest shareholder, small caps investor Otto Buttula, has taken a seat on the company's board.
